Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$30.83
-0.91-2.87%
At close: -
$30.83
0.000.00%
After Hours: 4:22 PM EDT
Comments
Loading...
Janux Therapeutics Analyst Ratings and Price Targets | NASDAQ:JANX | Benzinga
Janux Therapeutics Inc has a consensus price target of $81.18 based on the ratings of 12 analysts. The high is $200 issued by Cantor Fitzgerald on December 11, 2024. The low is $41 issued by Scotiabank on February 28, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Scotiabank, and Cantor Fitzgerald on March 3, 2025, February 28, 2025, and December 11, 2024, respectively. With an average price target of $103.67 between HC Wainwright & Co., Scotiabank, and Cantor Fitzgerald, there's an implied 236.25% upside for Janux Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Scotiabank
Cantor Fitzgerald
Stifel
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Janux Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 127.05% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | 32.99% | Scotiabank | George Farmer48% | $62 → $41 | Maintains | Sector Perform | Get Alert |
| 12/11/2024 | Buy Now | 548.72% | Cantor Fitzgerald | Josh Schimmer55% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 12/04/2024 | Buy Now | 101.1% | Scotiabank | George Farmer48% | $42 → $62 | Maintains | Sector Perform | Get Alert |
| 12/03/2024 | Buy Now | 273.01% | Stifel | Bradley Canino38% | $70 → $115 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 195.17% | Leerink Partners | Jeffrey La Rosa20% | $79 → $91 | Maintains | Outperform | Get Alert |
| 12/03/2024 | Buy Now | 127.05% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $63 → $70 | Maintains | Buy | Get Alert |
| 11/22/2024 | Buy Now | 156.24% | Leerink Partners | Jeffrey La Rosa20% | → $79 | Initiates | → Outperform | Get Alert |
| 11/07/2024 | Buy Now | 104.35% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 224.36% | Cantor Fitzgerald | Josh Schimmer55% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2024 | Buy Now | 123.81% | UBS | David Dai28% | → $69 | Initiates | → Buy | Get Alert |
| 09/16/2024 | Buy Now | 224.36% | Cantor Fitzgerald | Josh Schimmer55% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 127.05% | Stifel | Bradley Canino38% | → $70 | Initiates | → Buy | Get Alert |
| 08/19/2024 | Buy Now | 104.35% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $63 → $63 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 36.23% | Scotiabank | George Farmer48% | $47 → $42 | Maintains | Sector Perform | Get Alert |
| 08/08/2024 | Buy Now | 224.36% | Cantor Fitzgerald | Josh Schimmer55% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 140.03% | Wedbush | Robert Driscoll45% | $74 → $74 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2024 | Buy Now | 52.45% | Scotiabank | George Farmer48% | → $47 | Initiates | → Sector Perform | Get Alert |
| 05/13/2024 | Buy Now | 104.35% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $50 → $63 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 224.36% | Cantor Fitzgerald | Josh Schimmer55% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 05/08/2024 | Buy Now | 140.03% | Wedbush | Robert Driscoll45% | $53 → $74 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | 127.05% | JonesTrading | Soumit Roy46% | → $70 | Initiates | → Buy | Get Alert |
| 03/21/2024 | Buy Now | 101.1% | BTIG | Kaveri Pohlman26% | → $62 | Initiates | → Buy | Get Alert |
| 03/20/2024 | Buy Now | 224.36% | Cantor Fitzgerald | Josh Schimmer55% | → $100 | Initiates | → Overweight | Get Alert |
| 03/13/2024 | Buy Now | 55.69% | B of A Securities | Geoff Meacham63% | $24 → $48 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 62.18% | HC Wainwright & Co. | Swayampakula Ramakanth50% | $35 → $50 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 71.91% | Wedbush | David Driscoll53% | $24 → $53 | Maintains | Outperform | Get Alert |
| 11/13/2023 | Buy Now | 13.53% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2023 | Buy Now | -22.15% | Wedbush | Robert Driscoll45% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | -22.15% | Wedbush | Robert Driscoll45% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 13.53% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2023 | Buy Now | -22.15% | Wedbush | Robert Driscoll45% | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2023 | Buy Now | 13.53% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | -22.15% | Wedbush | Robert Driscoll45% | → $24 | Reiterates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 13.53% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $35 | Reiterates | → Buy | Get Alert |
| 04/06/2023 | Buy Now | -22.15% | Wedbush | Robert Driscoll45% | → $24 | Initiates | → Outperform | Get Alert |
| 03/13/2023 | Buy Now | 13.53% | HC Wainwright & Co. | Swayampakula Ramakanth50% | → $35 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | — | William Blair | Matt Phipps22% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Janux Therapeutics (JANX) stock?
The latest price target for Janux Therapeutics (NASDAQ:JANX) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $70.00 expecting JANX to rise to within 12 months (a possible 127.05% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Janux Therapeutics (JANX)?
The latest analyst rating for Janux Therapeutics (NASDAQ:JANX) was provided by HC Wainwright & Co., and Janux Therapeutics reiterated their buy rating.
When was the last upgrade for Janux Therapeutics (JANX)?
There is no last upgrade for Janux Therapeutics
When was the last downgrade for Janux Therapeutics (JANX)?
There is no last downgrade for Janux Therapeutics.
When is the next analyst rating going to be posted or updated for Janux Therapeutics (JANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Janux Therapeutics (JANX) correct?
While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a reiterated with a price target of $70.00 to $70.00. The current price Janux Therapeutics (JANX) is trading at is $30.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.